ArticleSovremennye tekhnologii v meditsine2026
Feasibility of Applying Proton Minibeam Technology on the Proton Therapy Complex "Prometheus".
Article in Sovremennye tekhnologii v meditsine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spatial fractionation of proton beams is being considered as a new strategy to reduce the probability of side-effects in radiation therapy on the proton therapy complex (PTC) "Prometheus". By collimating the beams to submillimeter dimensions, the dose profile at the target surface consists of alternating high- and low-dose regions. This promotes sparing of normal tissues along the beam path through the activation of various biological mechanisms. Materials and Methods: Collimation of the primary beam was achieved using brass multislit collimators. Mathematical modeling of the experiment was performed, and a phantom was irradiated from one and from two opposite directions. For effective summation of two fields and to achieve a homogeneous dose distribution in the target, intensity and energy modulation of the proton beams entering the collimator was carried out. To reduce errors caused by collimator deviation relative to the beam axis, a quality assurance system for collimator positioning on the treatment table was developed. Under the control of a scintillation detector and a laser positioner, positioning accuracy was within 0.2°. GafChromic EBT3 radiochromic films (Ashland, USA) were used as dosimeters. Results: When comparing calculated and experimental data, 90% of the distribution points matched the mathematical model according to the γ criterion (3%/3 mm). The quality of the minibeam field was assessed using the following parameters: valley-to-peak dose ratio; collimator throughput; ratio of the dose without the collimator to the dose with the collimator; and dose homogeneity index in the target. The obtained results met the quality assurance criteria for standard radiation therapy. Conclusion: Irradiation with proton minibeams using brass collimators is feasible on the PTC "Prometheus". A uniform dose distribution in the target area was experimentally achieved. The uniformity of coverage, the absence of local dose excesses, and the high dose gradient at the distal edge suggest that the described irradiation technique can be implemented on biological specimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.